Applied Therapeutics Granted Nasdaq Compliance Extension

The latest announcement is out from Applied Therapeutics ( (APLT) ).

Applied Therapeutics, Inc. received a notification from Nasdaq on February 7, 2025, regarding non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market. On August 13, 2025, Nasdaq granted the company an additional 180 days, until February 2, 2026, to regain compliance, transferring its listing to the Nasdaq Capital Market. The company is considering options like a reverse stock split to meet the requirement, with the risk of delisting if compliance is not achieved.

The most recent analyst rating on (APLT) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Applied Therapeutics stock, see the APLT Stock Forecast page.

Spark’s Take on APLT Stock

According to Spark, TipRanks’ AI Analyst, APLT is a Underperform.

Applied Therapeutics is in the early stages of revenue generation, but significant challenges in achieving profitability and sustaining operations through negative cash flow pose risks. The technical analysis shows downward momentum, and valuation metrics reflect its current unprofitability. Focus remains on operational improvements and expense management to navigate financial instability.

To see Spark’s full report on APLT stock, click here.

More about Applied Therapeutics

Average Trading Volume: 2,025,720

Technical Sentiment Signal: Sell

Current Market Cap: $62.29M

Find detailed analytics on APLT stock on TipRanks’ Stock Analysis page.